Human Alpha Thrombin, recombinant



Order
Quantity
Price
Status
100 NIH Units 200 € available


Documents
Art. No. T222
Synonym Coagulation factor IIa, α Thrombin, fibrinogenase, thrombase, activated blood coagulation factor II
Molecular Weight 38 kDa
Source Full-length DNS sequence for hn thrombin, IMAGE clone 77998, produced serum-free in stable HEK293 cells, purified from culture supernatant. Generated by activation of recombinant human Prethrombin II (expressed in HEK293 cells) with Ecarin
Activity Tested in fibrinogen polymerisation and FXIII-Assay
Appearance White lyophilized solid
Formulation Lyophilized from 20 mM TrisHCl, 150 mM NaCl, pH 7.2
Reconstitution Add 0.2 mL of water.
After reconstitution the solution should be stored at -20°C in working aliquots.
Avoid repeated freezing and thawing. Short time storage up to 48 h at 2-8°C is possible.
Application Coagulation research, medical research, protein-structure, sequence analysis, and biochemical research.
Working dilutions Optimal dilutions should be determined by the end user.
Storage 2-8°C
Delivery at ambient temperature is possible
Note INTENDED FOR RESEARCH USE ONLY, NOT FOR USE IN HUMAN, THERAPEUTIC OR DIAGNOSTIC APPLICATIONS.

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of non-alcoholic fatty liver disease (NAFLD)
  • Zedira publication - Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease
  • Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • imagePress release: Zedira announces ISO 9001:2015 certification

Blog  

  • DZG Aktuell: „Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227“
  • imageDesign of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
  • imageMicrobial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering

Events

  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy